Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

NCT00963534 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: lenalidomide, bendamustine, rituximab
DRUG: lenalidomide, bendamustine, rituximab

Sponsor

Lund University Hospital

Collaborators

[object Object]
[object Object]
[object Object]